An Open-Label Study of Risperidone in the Improvement of Quality of Life and Treatment of Symptoms of Violent and Self-Injurious Behaviour in Adults with Intellectual Disability

Background We examined the benefits of risperidone, including quality of life (QoL), in the treatment of violent and self-injurious behaviour in adults with moderate, severe or profound intellectual disability. Methods Twenty-four participants received open-label, oral, flexible-dose risperidone of 0.5–6 mg/day for 12 weeks. Efficacy was measured primarily using the Aberrant Behaviour Checklist (ABC) and secondarily using validated measures of depression, autism, QoL and global condition. Safety and tolerability were also assessed. Results Total ABC significantly improved from baseline by week 1. This improvement was maintained throughout the study (final visit, P < 0.001). Secondary efficacy measures were also improved with risperidone, including QoL measures (final visit: home life, P < 0.001; activity, P = 0.002; skills, P = 0.014). Risperidone was generally well tolerated, with no unexpected adverse events. Conclusions In this open-label trial, risperidone was efficacious and well tolerated for managing violent and self-injurious behaviour and improving QoL in adults with moderate, severe or profound intellectual disability

[1]  A. Došen.  Diagnosis and treatment of psychiatric and behavioural disorders in mentally retarded individuals: the state of the art. , 2008, Journal of intellectual disability research : JIDR.

[2]  L. Thorpe,et al.  Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders , 2005, Psychopharmacology.

[3]  R. Murray,et al.  Predictors of antisocial personality , 2004, British Journal of Psychiatry.

[4]  Abraham Weizman,et al.  The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. , 2003, The Journal of clinical psychiatry.

[5]  A. Swann,et al.  Neuroreceptor mechanisms of aggression and its treatment. , 2003, The Journal of clinical psychiatry.

[6]  M. Aman,et al.  Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  C. Binder,et al.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. , 2002, Pediatrics.

[8]  R. Findling,et al.  Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. , 2002, The American journal of psychiatry.

[9]  D. Felce,et al.  Service support to people in Wales with severe intellectual disability and the most severe challenging behaviours: processes, outcomes and costs. , 2002, Journal of intellectual disability research : JIDR.

[10]  S R Schroeder,et al.  Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. , 2001, American journal of mental retardation : AJMR.

[11]  D. Felce,et al.  Living with support in a home in the community: predictors of behavioral development and household and community activity. , 2001, Mental retardation and developmental disabilities research reviews.

[12]  D. Taylor,et al.  Atypical antipsychotics and weightgain — a systematic review , 2000, Acta psychiatrica Scandinavica.

[13]  M. Schluchter,et al.  A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[14]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[15]  F. Symons,et al.  Treatment of self-injurious behavior and quality of life for persons with mental retardation. , 1999, Mental retardation.

[16]  G. Baird,et al.  Psychopharmacotherapy in children and adults with intellectual disability , 1999, The Lancet.

[17]  C. McDougle,et al.  Brief Report: Two-Year Control of Behavioral Symptoms with Risperidone in Two Profoundly Retarded Adults with Autism , 1999, Journal of autism and developmental disorders.

[18]  K. Offord,et al.  The Autonomic Symptom Profile , 1999, Neurology.

[19]  S A Cohen,et al.  Risperidone for Aggression and Self-Injurious Behavior in Adults with Mental Retardation , 1998, Journal of autism and developmental disorders.

[20]  S. Read.  Self-injury and violence in people with severe learning disabilities , 1998, British Journal of Psychiatry.

[21]  R. Nicolson,et al.  An open trial of risperidone in young autistic children. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  C. McDougle,et al.  Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[23]  E. W. Simon,et al.  Substituting traditional antipsychotics with risperidone for individuals with mental retardation. , 1996, Mental retardation.

[24]  A. Labelle,et al.  Risperidone in the Treatment of Pervasive Developmental Disorder , 1994, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[25]  P. Thiry,et al.  Risperidone as add‐on therapy in behavioural disturbances in mental retardation: a double‐blind placebo‐controlled cross‐over study , 1993, Acta psychiatrica Scandinavica.

[26]  C. Gillberg,et al.  Autistic Symptoms in Children with Infantile Hydrocephalus , 1991, Acta paediatrica Scandinavica.

[27]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[28]  L. Sireling.  Depression in Mentally Handicapped Patients: Diagnostic and Neuroendocrine Evaluation , 1986, British Journal of Psychiatry.

[29]  M. Aman,et al.  The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. , 1985, American journal of mental deficiency.

[30]  A. Došen.  Applying the developmental perspective in the psychiatric assessment and diagnosis of persons with intellectual disability: part I--assessment. , 2005, Journal of intellectual disability research : JIDR.

[31]  E. Emerson,et al.  The prevalence of challenging behaviors: a total population study. , 2001, Research in developmental disabilities.

[32]  Marc van Bellinghen,et al.  Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. , 2001 .

[33]  J. Buitelaar.  Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. , 2000, Journal of child and adolescent psychopharmacology.

[34]  M. Wiznitzer,et al.  An open clinical trial of risperidone monotherapy in young children with autistic disorder. , 1997, Psychopharmacology bulletin.

[35]  C. McDougle,et al.  Risperidone in Adults with Autism or Pervasive Developmental Disorder , 1995 .